A neurodegeneration therapeutics company focused on treating Alzheimer's disease and other neurodegenerative disorders by blocking tau aggregation.

ASCE Neuron

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders.

Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.


Further information: www.asceneuron.com


Michael J. Fox Foundation

Johnson & Johnson Robotics and Digital Solutions

Kurma Partners

Sofinnova Partners

SR One

M Ventures

Asceneuron SA

#Asceneuron_sa announces $100 million oversubscribed Series C financing!
 
Today we announce that we have successfully secured a Series C financing, led by Novo Holdings with new investment from EQT Group Life Sciences, OrbiMed and SR One Capital Management Capital Management, alongside participation from existing investors M Ventures , Sofinnova Partners, GSK Equities Investment Limited and Johnson & Johnson Innovation JJDC Inc.
 
The funds will be used to advance our lead asset #ASN51, an oral small molecule drug designed to inhibit #OGA into Phase 2 clinical development for the treatment of Alzheimer’s disease. 
 
Click here https://lnkd.in/d278vevG to read the press release and discover more about Asceneuron’s groundbreaking clinical pipeline of O-GlcNAcase inhibitors for the treatment of #neurodegenerative diseases.

#neurodegeneration #ALS #alzheimers #parkinson #dementia #financing

#Asceneuron_sa announces $100 million oversubscribed Series C financing!
 
Today we announce that we have successfully secured a Series C financing, led by Novo Holdings with new investment from EQT Life Sciences, OrbiMed and SR One Capital Management, alongside participation from existing investors M Ventures , Sofinnova Partners, @GSK Equities Investment Limited and Johnson & Johnson Innovation JJDC Inc.
 
The funds will be used to advance our lead asset #ASN51, an oral small molecule drug designed to inhibit OGA into Phase 2 clinical development for the treatment of Alzheimer’s disease. 
 
Click the link in the comments below to read the press release and discover more about Asceneuron’s groundbreaking clinical pipeline of O-GlcNAcase (#OGA) inhibitors for the treatment of #neurodegenerative diseases.
 
#neurodegeneration #ALS #alzheimers #parkinson #dementia #financing

Asceneuron SA is pleased to announce the expansion of its Scientific Advisory Board (#SAB), with the appointments of world leading experts in neurodegenerative disease, Dr Samantha B., Henrik Zetterberg, MD, PhD, Rik Ossenkoppele, PhD, and Chris Van Dyck, MD.
 
The Scientific Advisory Board have vast experience in clinical trial design and biomarkers and will support #Asceneuron_sa as it advances its lead asset ASN51, a best-in-class, orally delivered, OGA inhibitor targeting tau aggregation in Alzheimer’s Disease into Phase II clinical development.
 
#Alzheimers #SAB #neurodegeneration
 
 https://lnkd.in/dz96PcHP

#Asceneuron_SA is delighted to announce the appointment of Barbara Angehrn Pavik as the new Chief Executive Officer (CEO), as part of a leadership transition poised to propel the company into its next phase of growth, with two compounds in clinical development.
Dirk Beher, co-founder of Asceneuron, its original Chief Scientific Officer, and CEO since 2014, will transition to the key role of Chief Scientific Advisor.

👉 https://lnkd.in/ezzmFNAp

Asceneuron SA is thrilled to announce it has joined the @CPathInstitute’s ‘Critical Path Alzheimer’s Disease’ (CPAD) Consortium and will contribute its expertise in #neurodegenerativedisease to advance biomarkers for #drugdevelopment in #alzheimersdisease, such as tau Positron Emission Tomography (tau-PET).
 
With our highly experienced team and world class Scientific Advisory Board of leading experts in neurodegenerative disease, we are honored to begin collaborating with the #CPAD to accelerate and develop new treatment therapies for the benefit of patients with Alzheimer’s disease. Read more via the link in the comments!
 
Follow #Asceneuron as we progress into Phase II clinical development later this year with our lead asset, ASN51, a potential best-in-class, orally administered, OGA inhibitor targeting tau aggregation.
 
#alzheimers #dementia #neurodegeneration #CPAD

COM:ASCENEURON

ASCE Neuron

Financials Not Available